Stimuli-responsive bioengineered platforms for precision cancer therapy

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Stimuli-responsive bioengineered platforms are redefining cancer therapy by shifting therapeutic design from systemic drug exposure toward context-dependent activation within malignant tissue. These systems are engineered to sense and respond to tumor-associated or externally applied cues, including acidic pH, redox imbalance, hypoxia, enzymatic activity, reactive oxygen species, temperature variation, light, ultrasound, and magnetic fields. Across the reviewed evidence, their principal value lies not merely in drug encapsulation but in the coordinated control of localization, release, intracellular access, multimodal therapy, microenvironment modulation, and safety. The field encompasses diverse architectures, including biomacromolecular nanoparticles, hydrogels, nanogels, polymeric micelles, prodrug assemblies, lipid-based systems, mesoporous silica, metal–organic frameworks, carbon-based materials, magnetic nanocomposites, and hybrid inorganic–organic constructs. These platforms have been validated in multiple cancer models through assays of uptake, cytotoxicity, apoptosis, spheroid penetration, tumor suppression, metastasis, recurrence, immune activation, stromal remodeling, and systemic tolerability. Collectively, the evidence supports a conceptual transition from passive nanocarriers to programmable therapeutic systems capable of aligning therapeutic action with the spatial, temporal, and biological heterogeneity of tumors. However, translation remains constrained by formulation complexity, incomplete standardization, limited long-term safety and biodistribution data, insufficient penetration into protected tumor niches, and the need for clinically relevant models that capture patient-level heterogeneity. Future progress will depend on rationally simplified architectures, quantitative stimulus–response validation, scalable manufacturing, integrated safety assessment, and biomarker-guided selection of platforms matched to defined tumor microenvironments. Stimuli-responsive bioengineering therefore represents a promising, although still maturing, foundation for safer, more selective, and more mechanistically coordinated precision cancer therapy.